Betasone Betamethasone (micronized) 0.5mg Tablets GENERIC NAME: Betamethasone (micronized) COMPOSITION: Each tablet contains: Active ingredient: Betamethasone (micronised) 0.5mg Excipients: Lactose monohydrate, corn starch, gelatin, Dye, FD & C blue,magnesium stearate. PHARMACEUTICAL FORM: Blue round flat ,beveled ,single tablet scored from one side.(scoring is non functional ) CONTRAINDICATIONS: Do not administer to the following patients: 1) Patients with a history of hypersensitivity to the ingredients of this drug. 2) Desmopressin acetate hydrate (for nocturnal enuresis) (see Interactions section) GENERAL CONTRAINDICATION: Generally, do not administer to the following patients, but administer with caution if particularly necessary: 1) Patients with infections or systemic mycosis for which there are no effective antibacterial agents [Symptoms may be exacerbated by immunosuppressive effects]. 2) Patients with peptic ulcer (ulcer Healing (tissue repair) may be compromised). 3) Patients with psychosis [It may affect neurotransmitters in the limbic system and exacerbate symptoms.] 4) Patients with tuberculosis disease [symptoms exacerbated due to immunosuppression . 5) Patients with herpes simplex keratitis [Symptoms may be aggravated by immune function suppression.] 6) Patients with posterior capsule cataract [symptoms may be exacerbated.] 7) Patients with glaucoma [Glaucoma may be aggravated by increased intraocular pressure.] 8) Patients with hypertension [hypertension may be aggravated by electrolyte metabolism.] 9) Patients with electrolyte abnormalities [Electrolyte abnormalities may be aggravated by electrolyte metabolism.] 10) Patients with thrombosis [There is a case where sometimes Symptoms are exacerbated by blood coagulation.] 11) Patients with recent visceral surgical wounds on internal organs [Wound healing (tissue repair) may be impaired.] 12) Patients with acute myocardial infarction [There is a report of cardiac rupture.] INDICATIONS AND EFFECTS: *Chronic adrenal cortical insufficiency (primary, secondary, pituitary, iatrogenic), *acute adrenal cortical insufficiency (adrenal crisis), *adrenal genital syndrome, *sub-acute thyroiditis, thyrotoxicosis [thyroid (toxic) crisis], malignant ocular protrusion with thyroid disease, *isolated ACTH deficiency, *Pituitary suppression test. * Rheumatoid arthritis, juvenile rheumatoid arthritis (including Still's disease), rheumatic fever (including rheumatic carditis), polymyalgia rheumatic, lupus erythematosus (systemic and chronic discoid), systemic vasculitis (including Takayasu's arteritis, polyarteritis nodosa, microscopic polyangiitis, granulomatosis polyangiitis), polymyositis (dermatomyositis) , scleroderma nephrosis and nephrotic syndrome. *"Congestive heart failure *Bronchial asthma, asthmatic bronchitis (including pediatric asthmatic bronchitis), *Drugs Allergies/poisoning (including drug eruptions and toxic eruptions) due to drugs or other chemical substances), serum sickness, *Severe infection (to be used in combination with chemotherapy) *Hemolytic anemia (immune or suspected immune mechanism), leukemia (acute leukemia, acute conversion of chronic myeloid leukemia, chronic lymphocytic leukemia disease) (including cutaneous leukemia), granulocytopenia (essential, secondary), purpura disease (thrombocytopenic and non-thrombocytopenic), aplastic anemia, Bleeding diathesis due to disorders of clotting factors, Localized enteritis, ulcerative colitis. *Improvement of the general condition of severe debilitating diseases (including terminal cancer). *Fulminant hepatitis (including those considered clinically severe), acute cholestatic hepatitis, chronic hepatitis (active, acute, relapsing, cholestatic type) (limited to refractory cases in which marked abnormalities in liver function persist without responding to general treatment), liver cirrhosis (active type, accompanied by refractory ascites, accompanied by cholestasis) ) *Sarcoidosis (excluding bilateral hilar lymphadenopathy only), diffuse interstitial pneumonia (pulmonary fibrosis) (including radiation pneumonitis), pulmonary tuberculosis (limited to miliary tuberculosis and severe tuberculosis) (concomitant use with anti-tuberculosis drugs), tuberculous meningitis (used in combination with anti-tuberculous drugs), tuberculous pleuritis (used in combination with anti-tuberculous drugs), tuberculous peritonitis (used in combination with anti-tuberculous drugs), tuberculous pericarditis (used in combination with anti- tuberculous drugs). *Encephalomyelitis (including encephalitis and myelitis) (however, in the case of primary encephalitis, this should be used for a short period of time when symptoms of intracranial hypertension are observed and other drugs are not sufficiently effective), peripheral neuritis (including Guillain-Barre syndrome), dystonia, myasthenia gravis, multiple sclerosis (including optic myelitis), chorea minor, facial paralysis, spinal arachnoiditis. *Malignant lymphoma (lymphosarcomatosis, reticulosarcomatosis, Hodgkin's disease, cutaneous radiculopathy, mycosis fungoides) and similar diseases (related diseases), acidophilic granuloma, recurrent metastasis of breast cancer. *Idiopathic hypoglycemia. *"Fever of unknown cause". *Adrenalectomy, organ/tissue transplantation, post-invasive pulmonary edema, adrenal insufficiency after Surgical intervention for patients. *Snake venom/insect venom (including severe insect bites). *Ankylosing spondylitis (rheumatic spondylitis). *Prevention of adhesions after salpingoplasty, ovulation disorders due to adrenal cortical dysfunction, prostate cancer (when other therapies are ineffective), penile induration. ● Eczema/dermatitis group (acute eczema, sub-acute eczema, chronic eczema, contact dermatitis, nummular eczema, auto sensitized dermatitis, atopic dermatitis, breast/juvenile/pediatric eczema, Lichen simplex, other Neurodermatitis, seborrhea dermatitis, progressive Palmoplantar keratoderma , other finger dermatitis, genital or anal eczema, auricular and external auditory canal eczema/dermatitis, nasal vestibule and nasal alar (However, do not administer as much as possible except for severe cases). ● Prurigo (including infantile strophulus, lichen urticatus, fixed urticatus) (However, this is limited to severe cases. Local injection is desirable for fixed urticaria.), urticaria , Measles (excluding chronic cases) (limited to severe cases). ● Psoriasis and similar symptoms [dry plaque Psoriasis vulgaris (severe cases), psoriatic arthritis, erythrodermic psoriasis, pustular psoriasis, acrodermatitis, impetigo herpetiformis, Reiter’s syndrome], parapsoriasis (limited to severe cases), ● Palmoplantar pustulosis (limited to severe cases), ● outbreak of erythema pilaris eruption (limited to severe cases). ● lichen planus (limited to severe cases) ● adult edematous Sclerosis, erythema (●erythema multiform exudativum, erythema nodosum) (however in the case of erythema multiform exudativum (its use is, limited to severe cases), IgA vasculitis ( it is limited to severe cases), Weber-Christian disease, mucocutaneous ocular syndrome, Stevens-Johnson disease, cutaneous stomatitis, Fuchs syndrome group, Behcet’s disease (in the absence of ocular symptoms), Lipschutz ulcer, Raynaud’s disease. ● Alopecia areata (limited to malignant types), pemphigus group (Pemphigus vulgaris, pemphigus foliaceus, Senear-Usher syndrome, proliferative pemphigus), During herpetiform dermatitis (including pemphigoid, herpes gestationis)), congenital epidermolysis bullosa, herpes zoster (limited to severe cases). ● Erythroderma (including pityriasis rubra pilaris), disseminated miliary lupus of the face (limited to severe cases), allergic vasculitis and similar diseases (pityriasis lichenoid), chronic ulcerative pyoderma, sclerema neonatorum , Symptomatic treatment of inflammatory diseases of the inner eye, optic nerve, orbit, and eye muscle (uvea inflammation, chorioretinitis, retinal vasculitis, optic neuritis, orbital inflammatory pseudo tumor, orbit infundibular apex syndrome, ophthalmoplegia), inflammatory diseases of the extra ocular and anterior ocular segments. If eye drops are inappropriate or insufficient for symptomatic treatment (blepharitis, conjunctivitis, keratitis, scleritis, iridocyclitis), postoperative inflammation in the ophthalmic area. * Acute/chronic otitis media, otitis media with effusion, eustachian tube stenosis, Meniere’s disease and Meniere’s syndrome, acute sensor neural hearing loss, vasomotor (neuro) rhinitis, Allergic rhinitis, hay fever, sinusitis/nasal polyps, progressive gangrenous rhinitis, laryngitis, laryngeal edema, laryngeal polyps, nodules, inflammation of the esophagus (corrosive esophagitis, after using a direct scope) and after esophageal dilatation, otorhinolaryngological area. *Postoperative therapy after local surgery. *Refractory stomatitis and glossitis (those that cannot be cured with local therapy), acute/chronic (recurrent) sialadenitis (salivary gland infection). ● This mark means: Use only when the effect of topical preparations is insufficient or when it is assumed that adequate effects cannot be expected.
